Pharmaceuticals company Aurobindo Pharma announced Q1FY25 results: Revenue from Operations increased by 10.5% YoY to Rs 7,567 crore with growth across the businesses US formulations (excluding Puerto Rico) revenue increased by 13.3% YoY to Rs 3,555 crore (USD 426 million) Europe formulations revenue increased by 7.9% YoY to Rs 1,982 crore (EUR 221 million) Growth Markets revenue increased by 49.2% YoY to Rs 709 crore (USD 85 million) ARV revenue increased by 13.9% YoY to Rs 229 crore (USD 27 million) API revenue grew by 5.6% YoY to Rs 1,092 crore (USD 131 million) EBITDA before Forex and Other Income stood at Rs 1,620 crore; EBITDA margin at 21.4% Research & Development (R&D;) spend was Rs 339 crore, 4.5% of revenues Received final approval for 10 ANDAs including 1 Specialty & Injectable product from the USFDA Net Profit after Share of Profit/Loss of JV and Minority Interest at Rs 919 crore, vs. Rs 571 crore in Q1FY24 Basic & Diluted EPS grew by 61.4% YoY to Rs 15.69 per share Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We are pleased with our continued strong performance this quarter, with a significant top-line growth across all our business segments. Our profitability was sustained by improved gross margins and operational efficiencies, while ramping-up our recently commercialized plants. We are confident in our ability to achieve our growth targets for FY25.” Result PDF